Retinal Imaging Biomarkers and Endpoints Summit on June 13-15, 2023 in Boston, United States

Uniting biotech and pharma scientists to revolutionize ophthalmic drug development, the Retinal Imaging Biomarkers and Endpoints Summit encourages forward-thinking discussions to enhance the adoption of novel imaging-based approaches to determine retinal function and optimize development of regulatory accepted endpoints.

Join 60+ retinal imaging, innovation, R and D, preclinical and clinical experts from the likes of Genentech, AbbVie, Apellis, Janssen and Novartis to overcome the translational challenges of choosing and implementing novel ophthalmic imaging biomarkers and endpoints in your research, to accelerate earlier, non-invasive and personalised healthcare for ophthalmic and neurodegenerative patients.

URLs:

Tickets: https://go.evvnt.com/1549947-1?pid=10008

Brochure: https://go.evvnt.com/1549947-3?pid=10008

Time: 9:00 am - 5:00 pm

Prices:

Drug Developer Pricing - Conference + Workshop Day: USD 4297.00,

Drug Developer Pricing - Conference Only: USD 2999.00,

Standard Pricing - Conference + Workshop Day: USD 5297.00,

Standard Pricing - Conference Only: USD 3799.00

Speakers: Sairam Bellum, Senior Principal Scientist, Merck, Daniel Chao, Senior Director - Translational, Experimental Medicine and Retina Clinical lead, Janssen, Victor Chong, Vice President and Global Head of Retina, Janssen, Tara DeSilva, Associate Professor, Cleveland Clinic, Kamal Dhakal, Eye Care Scientist, AbbVie, David Esposito, President and Chief Executive Officer, ONL Therapeutics, Simon Gao, Senior Scientist - Clinical Imaging, Genentech, Jing Hua, Medical Director, Boehringer Ingelheim, Ashwath Jayagopal, Chief Scientific Officer, Opus Genetics, Katie Litts, Scientist, Genentech, Mila Malhotra, Director - Medical and Clinical Development, REGENXBIO, Alex McKeown, Director - Translational Ophthalmology and Digital Programs Lead, Apellis, Samarendra Mohanty, Chief Scientific Officer, Nanoscope Therapeutics, Richard Nicholas, Professor of Practice Neurology, Imperial College London, Guillaume Normand, Director - Clinical Development, Novartis, David Esposito, President and Chief Executive Officer, ONL Therapeutics, Srinivas Sadda, President and Chief Scientific Officer, Doheny Eye Institute, Michael Tolentino, Co-Founder and Chief Scientific Officer, Aviceda Therapeutics, Paul Wille, Director - Product Development and Scientist, Abeona Therapeutics, Daniela Ferrara, Senior Director of Ophthalmology, Genentech, Khaled Nassar, Principal Expert Retinal Health, Principal Clinical Biomarker Lead, Boehringer Ingelheim